The Business Times

Pharmaceuticals

International

WHO warns against three India-made cough syrups after child deaths

Singapore mainly exports active pharmaceutical ingredients to the US, instead of finished products like tablets and capsules. Between 2022 and 2024, Singapore’s pharmaceutical exports to the US averaged S$3.7 billion per year.
Singapore

Singapore-based pharma companies waiting for confirmation of US tariff exemptions: MTI

The company currently operates a commercial site at Gurugram near India’s capital, New Delhi, and has specialised operations at Bengaluru and Hyderabad.
Consumer & Healthcare

Eli Lilly to invest US$1 billion in India contract manufacturing

Pfizer’s top-selling drugs include the blood-thinner Eliquis, the pneumonia vaccine Prevnar, and a shot and pill for Covid-19.
Consumer & Healthcare

Pfizer’s drug price cuts yield three-year Trump tariff reprieve

Pharmaceutical exports to the US account for about S$4 billion of the Republic’s exports, says Deputy Prime Minister Gan Kim Yong.
Singapore

New US pharmaceutical tariffs may have ‘no immediate impact’ on drugmakers: DPM Gan

Less-than-favourable valuations for biopharma companies may be a key reason behind the lack of such companies listing on the SGX.
Singapore

The biopharma scene in Singapore is vibrant, but few make it to SGX

Pharmaceutical firms that have broken ground on US facilities will receive exemptions.
Singapore

Trump’s pharma tariffs put Singapore at ‘greatest risk’ among major exporters if no exemptions granted: economists

The winning portfolio of the year is still that of a 60-40 globally diversified portfolio.
Companies & Markets

‘Finally’: Citi investment strategist lauds SGX initiatives, says ‘no reason’ Hong Kong should dominate Asian equity markets

In Japan, Sumitomo Pharma tumbled 4.3 per cent, Otsuka Holdings dropped 3.5 per cent, and Daiichi Sankyo lost 1.6 per cent, although Takeda added 0.2 per cent and Shionogi gained 1.3 per cent.
Capital Markets & Currencies

Shares of Asian drugmakers drop after Trump threatens tariffs

US President Donald Trump speaks to members of the media in the Oval Office of the White House in Washington, DC, US, on Friday, Sept. 19, 2025. Trump is signing a proclamation that would move to extensively overhaul the H-1B visa program, requiring a $100,000 fee for applications in a bid to curb overuse, according to a White House official familiar with the matter. Photographer: Aaron Schwartz/CNP/Bloomberg
Global Enterprise

Trump says US will impose 100% tariffs on imported branded or patented pharmaceuticals from Oct 1

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More